Neutropenic Fever
- PMID: 39437061
- Bookshelf ID: NBK608289
- DOI: 10.1007/978-3-031-44080-9_35
Neutropenic Fever
Excerpt
Fever during neutropenia is almost universal after an HCT. In neutropenic HCT recipients, clinicians are faced with a unique combination of issues: (1) high incidence of bacterial bloodstream infections, (2) high mortality in case of infections due to Gram-negative bacteria unless effective antibiotic treatment is provided promptly, and (3) numerous causes of fever other than bacterial infection.
Copyright 2024, The Author(s).
Sections
References
-
- Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4:e573–83. - PubMed
-
- Averbuch D, Orasch C, Cordonnier C. ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98:1826–35. - PMC - PubMed
-
- Averbuch D, Tridello G, Hoek J, et al. Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017;65(11):1819–28. - PubMed
-
- de Jonge NA, Sikkens JJ, Zweegman S, et al. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. Lancet Haematol. 2022;9(8):e563–72. - PubMed
Publication types
LinkOut - more resources
Full Text Sources